nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—RRM2—urinary bladder cancer	0.281	1	CbGaD
Cladribine—Azacitidine—Gemcitabine—urinary bladder cancer	0.094	0.512	CrCrCtD
Cladribine—Decitabine—Gemcitabine—urinary bladder cancer	0.0895	0.488	CrCrCtD
Cladribine—POLE—Gemcitabine—urinary bladder cancer	0.0824	0.237	CbGbCtD
Cladribine—RRM2—Gemcitabine—urinary bladder cancer	0.0548	0.158	CbGbCtD
Cladribine—RRM1—Gemcitabine—urinary bladder cancer	0.0548	0.158	CbGbCtD
Cladribine—SLC28A3—Gemcitabine—urinary bladder cancer	0.0473	0.136	CbGbCtD
Cladribine—POLA1—Gemcitabine—urinary bladder cancer	0.0473	0.136	CbGbCtD
Cladribine—DCK—Gemcitabine—urinary bladder cancer	0.0292	0.0839	CbGbCtD
Cladribine—SLC22A2—Cisplatin—urinary bladder cancer	0.00611	0.0176	CbGbCtD
Cladribine—ABCG2—Fluorouracil—urinary bladder cancer	0.00531	0.0153	CbGbCtD
Cladribine—ABCG2—Carboplatin—urinary bladder cancer	0.00528	0.0152	CbGbCtD
Cladribine—ABCG2—Cisplatin—urinary bladder cancer	0.00451	0.013	CbGbCtD
Cladribine—ABCG2—Etoposide—urinary bladder cancer	0.00443	0.0128	CbGbCtD
Cladribine—ABCG2—Doxorubicin—urinary bladder cancer	0.00302	0.0087	CbGbCtD
Cladribine—ABCG2—Methotrexate—urinary bladder cancer	0.00293	0.00843	CbGbCtD
Cladribine—POLE2—prostate gland—urinary bladder cancer	0.00231	0.0583	CbGeAlD
Cladribine—POLE4—renal system—urinary bladder cancer	0.0018	0.0455	CbGeAlD
Cladribine—POLE4—female reproductive system—urinary bladder cancer	0.00145	0.0364	CbGeAlD
Cladribine—RRM2B—prostate gland—urinary bladder cancer	0.00136	0.0342	CbGeAlD
Cladribine—POLE3—prostate gland—urinary bladder cancer	0.00128	0.0324	CbGeAlD
Cladribine—SLC28A3—prostate gland—urinary bladder cancer	0.0012	0.0303	CbGeAlD
Cladribine—RRM2B—seminal vesicle—urinary bladder cancer	0.00115	0.0289	CbGeAlD
Cladribine—POLE2—vagina—urinary bladder cancer	0.00114	0.0288	CbGeAlD
Cladribine—POLE3—seminal vesicle—urinary bladder cancer	0.00109	0.0274	CbGeAlD
Cladribine—PNP—renal system—urinary bladder cancer	0.000998	0.0251	CbGeAlD
Cladribine—POLE—prostate gland—urinary bladder cancer	0.00098	0.0247	CbGeAlD
Cladribine—RRM2B—renal system—urinary bladder cancer	0.000926	0.0233	CbGeAlD
Cladribine—RRM2B—urethra—urinary bladder cancer	0.00091	0.0229	CbGeAlD
Cladribine—POLE3—renal system—urinary bladder cancer	0.000876	0.0221	CbGeAlD
Cladribine—POLE3—urethra—urinary bladder cancer	0.00086	0.0217	CbGeAlD
Cladribine—POLA1—prostate gland—urinary bladder cancer	0.000845	0.0213	CbGeAlD
Cladribine—POLE—seminal vesicle—urinary bladder cancer	0.000829	0.0209	CbGeAlD
Cladribine—RRM2—prostate gland—urinary bladder cancer	0.000807	0.0203	CbGeAlD
Cladribine—PNP—female reproductive system—urinary bladder cancer	0.000799	0.0201	CbGeAlD
Cladribine—Floxuridine—TYMP—urinary bladder cancer	0.000758	0.289	CrCbGaD
Cladribine—RRM2B—female reproductive system—urinary bladder cancer	0.000742	0.0187	CbGeAlD
Cladribine—POLE2—lymph node—urinary bladder cancer	0.000739	0.0186	CbGeAlD
Cladribine—POLA1—seminal vesicle—urinary bladder cancer	0.000714	0.018	CbGeAlD
Cladribine—POLE3—female reproductive system—urinary bladder cancer	0.000701	0.0177	CbGeAlD
Cladribine—NR5A1—female reproductive system—urinary bladder cancer	0.000679	0.0171	CbGeAlD
Cladribine—RRM2B—vagina—urinary bladder cancer	0.000671	0.0169	CbGeAlD
Cladribine—RRM1—prostate gland—urinary bladder cancer	0.00067	0.0169	CbGeAlD
Cladribine—POLE—urethra—urinary bladder cancer	0.000656	0.0165	CbGeAlD
Cladribine—POLE3—vagina—urinary bladder cancer	0.000634	0.016	CbGeAlD
Cladribine—Trifluridine—TYMP—urinary bladder cancer	0.000602	0.23	CrCbGaD
Cladribine—RRM1—seminal vesicle—urinary bladder cancer	0.000567	0.0143	CbGeAlD
Cladribine—POLA1—urethra—urinary bladder cancer	0.000566	0.0142	CbGeAlD
Cladribine—RRM2—renal system—urinary bladder cancer	0.00055	0.0139	CbGeAlD
Cladribine—POLE—female reproductive system—urinary bladder cancer	0.000535	0.0135	CbGeAlD
Cladribine—DCK—prostate gland—urinary bladder cancer	0.000521	0.0131	CbGeAlD
Cladribine—POLE—vagina—urinary bladder cancer	0.000484	0.0122	CbGeAlD
Cladribine—RRM1—smooth muscle tissue—urinary bladder cancer	0.000475	0.012	CbGeAlD
Cladribine—Clofarabine—RRM2—urinary bladder cancer	0.000468	0.179	CrCbGaD
Cladribine—RRM1—renal system—urinary bladder cancer	0.000457	0.0115	CbGeAlD
Cladribine—RRM1—urethra—urinary bladder cancer	0.000449	0.0113	CbGeAlD
Cladribine—RRM2—female reproductive system—urinary bladder cancer	0.000441	0.0111	CbGeAlD
Cladribine—DCK—seminal vesicle—urinary bladder cancer	0.00044	0.0111	CbGeAlD
Cladribine—RRM2B—lymph node—urinary bladder cancer	0.000434	0.0109	CbGeAlD
Cladribine—SLC22A2—renal system—urinary bladder cancer	0.000429	0.0108	CbGeAlD
Cladribine—POLA1—vagina—urinary bladder cancer	0.000417	0.0105	CbGeAlD
Cladribine—POLE3—lymph node—urinary bladder cancer	0.00041	0.0103	CbGeAlD
Cladribine—RRM2—vagina—urinary bladder cancer	0.000398	0.01	CbGeAlD
Cladribine—RRM1—female reproductive system—urinary bladder cancer	0.000366	0.00922	CbGeAlD
Cladribine—Floxuridine—TYMS—urinary bladder cancer	0.000356	0.136	CrCbGaD
Cladribine—DCK—urethra—urinary bladder cancer	0.000349	0.00878	CbGeAlD
Cladribine—RRM1—vagina—urinary bladder cancer	0.000331	0.00834	CbGeAlD
Cladribine—POLE—lymph node—urinary bladder cancer	0.000313	0.00788	CbGeAlD
Cladribine—SLC22A1—renal system—urinary bladder cancer	0.000303	0.00762	CbGeAlD
Cladribine—ABCG2—prostate gland—urinary bladder cancer	0.000291	0.00732	CbGeAlD
Cladribine—DCK—female reproductive system—urinary bladder cancer	0.000284	0.00716	CbGeAlD
Cladribine—Trifluridine—TYMS—urinary bladder cancer	0.000283	0.108	CrCbGaD
Cladribine—POLA1—lymph node—urinary bladder cancer	0.00027	0.00679	CbGeAlD
Cladribine—RRM2—lymph node—urinary bladder cancer	0.000258	0.00649	CbGeAlD
Cladribine—DCK—vagina—urinary bladder cancer	0.000257	0.00648	CbGeAlD
Cladribine—ABCG2—seminal vesicle—urinary bladder cancer	0.000246	0.00619	CbGeAlD
Cladribine—SLC22A1—vagina—urinary bladder cancer	0.000219	0.00552	CbGeAlD
Cladribine—POLE2—Epirubicin—Valrubicin—urinary bladder cancer	0.000218	0.1	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Valrubicin—urinary bladder cancer	0.000218	0.1	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Valrubicin—urinary bladder cancer	0.000218	0.1	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Valrubicin—urinary bladder cancer	0.000218	0.1	CbGdCrCtD
Cladribine—RRM1—lymph node—urinary bladder cancer	0.000214	0.00539	CbGeAlD
Cladribine—ABCG2—urethra—urinary bladder cancer	0.000195	0.0049	CbGeAlD
Cladribine—PNP—Daunorubicin—Valrubicin—urinary bladder cancer	0.000168	0.0772	CbGdCrCtD
Cladribine—DCK—lymph node—urinary bladder cancer	0.000166	0.00419	CbGeAlD
Cladribine—Adenosine monophosphate—SRC—urinary bladder cancer	0.000154	0.0587	CrCbGaD
Cladribine—POLE2—Teniposide—Etoposide—urinary bladder cancer	0.000146	0.0667	CbGdCrCtD
Cladribine—ABCG2—vagina—urinary bladder cancer	0.000143	0.00361	CbGeAlD
Cladribine—DCK—Epirubicin—Valrubicin—urinary bladder cancer	9.83e-05	0.0451	CbGdCrCtD
Cladribine—DCK—Doxorubicin—Valrubicin—urinary bladder cancer	9.83e-05	0.0451	CbGdCrCtD
Cladribine—ABCG2—lymph node—urinary bladder cancer	9.28e-05	0.00234	CbGeAlD
Cladribine—POLE2—Doxorubicin—Epirubicin—urinary bladder cancer	7.59e-05	0.0348	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Epirubicin—urinary bladder cancer	7.59e-05	0.0348	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Epirubicin—urinary bladder cancer	7.59e-05	0.0348	CbGdCrCtD
Cladribine—RRM1—Azacitidine—Gemcitabine—urinary bladder cancer	7.42e-05	0.034	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—urinary bladder cancer	7.02e-05	0.0322	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—urinary bladder cancer	7.02e-05	0.0322	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—urinary bladder cancer	7.02e-05	0.0322	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Gemcitabine—urinary bladder cancer	5.87e-05	0.0269	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Epirubicin—urinary bladder cancer	5.86e-05	0.0269	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Doxorubicin—urinary bladder cancer	5.42e-05	0.0249	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Gemcitabine—urinary bladder cancer	4.66e-05	0.0214	CbGdCrCtD
Cladribine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	3.85e-05	0.000526	CcSEcCtD
Cladribine—Body temperature increased—Cisplatin—urinary bladder cancer	3.85e-05	0.000525	CcSEcCtD
Cladribine—Fatigue—Etoposide—urinary bladder cancer	3.85e-05	0.000525	CcSEcCtD
Cladribine—Pain—Etoposide—urinary bladder cancer	3.82e-05	0.000521	CcSEcCtD
Cladribine—Constipation—Etoposide—urinary bladder cancer	3.82e-05	0.000521	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—urinary bladder cancer	3.81e-05	0.00052	CcSEcCtD
Cladribine—Urinary tract infection—Epirubicin—urinary bladder cancer	3.81e-05	0.00052	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—urinary bladder cancer	3.81e-05	0.000519	CcSEcCtD
Cladribine—Hypersensitivity—Fluorouracil—urinary bladder cancer	3.79e-05	0.000517	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	3.78e-05	0.000516	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—urinary bladder cancer	3.78e-05	0.000516	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—urinary bladder cancer	3.76e-05	0.000513	CcSEcCtD
Cladribine—Asthenia—Gemcitabine—urinary bladder cancer	3.75e-05	0.000512	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—urinary bladder cancer	3.74e-05	0.00051	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—urinary bladder cancer	3.72e-05	0.000507	CcSEcCtD
Cladribine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	3.71e-05	0.000506	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—urinary bladder cancer	3.7e-05	0.000505	CcSEcCtD
Cladribine—Pruritus—Gemcitabine—urinary bladder cancer	3.7e-05	0.000505	CcSEcCtD
Cladribine—Nausea—Thiotepa—urinary bladder cancer	3.69e-05	0.000504	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—urinary bladder cancer	3.69e-05	0.000503	CcSEcCtD
Cladribine—Feeling abnormal—Etoposide—urinary bladder cancer	3.68e-05	0.000502	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—urinary bladder cancer	3.65e-05	0.000498	CcSEcCtD
Cladribine—Gastrointestinal pain—Etoposide—urinary bladder cancer	3.65e-05	0.000498	CcSEcCtD
Cladribine—Pruritus—Fluorouracil—urinary bladder cancer	3.64e-05	0.000496	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—urinary bladder cancer	3.63e-05	0.000495	CcSEcCtD
Cladribine—Infestation—Doxorubicin—urinary bladder cancer	3.63e-05	0.000495	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	3.6e-05	0.000491	CcSEcCtD
Cladribine—Hypersensitivity—Cisplatin—urinary bladder cancer	3.59e-05	0.00049	CcSEcCtD
Cladribine—Diarrhoea—Gemcitabine—urinary bladder cancer	3.58e-05	0.000488	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—urinary bladder cancer	3.57e-05	0.000487	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—urinary bladder cancer	3.56e-05	0.000485	CcSEcCtD
Cladribine—Urticaria—Etoposide—urinary bladder cancer	3.55e-05	0.000484	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—urinary bladder cancer	3.54e-05	0.000483	CcSEcCtD
Cladribine—Abdominal pain—Etoposide—urinary bladder cancer	3.53e-05	0.000481	CcSEcCtD
Cladribine—Body temperature increased—Etoposide—urinary bladder cancer	3.53e-05	0.000481	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—urinary bladder cancer	3.53e-05	0.000481	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—urinary bladder cancer	3.53e-05	0.000481	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—urinary bladder cancer	3.52e-05	0.00048	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—urinary bladder cancer	3.52e-05	0.00048	CcSEcCtD
Cladribine—Diarrhoea—Fluorouracil—urinary bladder cancer	3.52e-05	0.00048	CcSEcCtD
Cladribine—Asthenia—Cisplatin—urinary bladder cancer	3.5e-05	0.000477	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—urinary bladder cancer	3.5e-05	0.000477	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—urinary bladder cancer	3.49e-05	0.000476	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—urinary bladder cancer	3.48e-05	0.000474	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—urinary bladder cancer	3.47e-05	0.000473	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—urinary bladder cancer	3.46e-05	0.000472	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—urinary bladder cancer	3.45e-05	0.000471	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	3.43e-05	0.000468	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—urinary bladder cancer	3.42e-05	0.000467	CcSEcCtD
Cladribine—DCK—Doxorubicin—Epirubicin—urinary bladder cancer	3.42e-05	0.0157	CbGdCrCtD
Cladribine—Angiopathy—Methotrexate—urinary bladder cancer	3.42e-05	0.000466	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—urinary bladder cancer	3.4e-05	0.000464	CcSEcCtD
Cladribine—Dizziness—Fluorouracil—urinary bladder cancer	3.4e-05	0.000464	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—urinary bladder cancer	3.39e-05	0.000463	CcSEcCtD
Cladribine—Chills—Methotrexate—urinary bladder cancer	3.38e-05	0.000461	CcSEcCtD
Cladribine—Diarrhoea—Cisplatin—urinary bladder cancer	3.33e-05	0.000455	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—urinary bladder cancer	3.33e-05	0.000454	CcSEcCtD
Cladribine—Alopecia—Methotrexate—urinary bladder cancer	3.33e-05	0.000454	CcSEcCtD
Cladribine—Vomiting—Gemcitabine—urinary bladder cancer	3.32e-05	0.000453	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—urinary bladder cancer	3.3e-05	0.00045	CcSEcCtD
Cladribine—Rash—Gemcitabine—urinary bladder cancer	3.3e-05	0.00045	CcSEcCtD
Cladribine—Dermatitis—Gemcitabine—urinary bladder cancer	3.29e-05	0.000449	CcSEcCtD
Cladribine—Eye disorder—Epirubicin—urinary bladder cancer	3.29e-05	0.000449	CcSEcCtD
Cladribine—Hypersensitivity—Etoposide—urinary bladder cancer	3.29e-05	0.000449	CcSEcCtD
Cladribine—Erythema—Methotrexate—urinary bladder cancer	3.28e-05	0.000447	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—urinary bladder cancer	3.28e-05	0.000447	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—urinary bladder cancer	3.28e-05	0.000447	CcSEcCtD
Cladribine—Headache—Gemcitabine—urinary bladder cancer	3.28e-05	0.000447	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—urinary bladder cancer	3.27e-05	0.000446	CcSEcCtD
Cladribine—Vomiting—Fluorouracil—urinary bladder cancer	3.27e-05	0.000446	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—urinary bladder cancer	3.26e-05	0.000445	CcSEcCtD
Cladribine—Rash—Fluorouracil—urinary bladder cancer	3.24e-05	0.000442	CcSEcCtD
Cladribine—Dermatitis—Fluorouracil—urinary bladder cancer	3.24e-05	0.000442	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—urinary bladder cancer	3.23e-05	0.000441	CcSEcCtD
Cladribine—Headache—Fluorouracil—urinary bladder cancer	3.22e-05	0.000439	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.22e-05	0.000439	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.21e-05	0.000438	CcSEcCtD
Cladribine—Asthenia—Etoposide—urinary bladder cancer	3.2e-05	0.000437	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.2e-05	0.000437	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—urinary bladder cancer	3.2e-05	0.000436	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—urinary bladder cancer	3.2e-05	0.000436	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—urinary bladder cancer	3.18e-05	0.000434	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.17e-05	0.000433	CcSEcCtD
Cladribine—Back pain—Methotrexate—urinary bladder cancer	3.17e-05	0.000432	CcSEcCtD
Cladribine—DCK—Epirubicin—Doxorubicin—urinary bladder cancer	3.16e-05	0.0145	CbGdCrCtD
Cladribine—Chills—Epirubicin—urinary bladder cancer	3.16e-05	0.000431	CcSEcCtD
Cladribine—Pruritus—Etoposide—urinary bladder cancer	3.16e-05	0.000431	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—urinary bladder cancer	3.15e-05	0.000429	CcSEcCtD
Cladribine—Alopecia—Epirubicin—urinary bladder cancer	3.11e-05	0.000425	CcSEcCtD
Cladribine—Nausea—Gemcitabine—urinary bladder cancer	3.11e-05	0.000424	CcSEcCtD
Cladribine—Vomiting—Cisplatin—urinary bladder cancer	3.1e-05	0.000423	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—urinary bladder cancer	3.09e-05	0.000421	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.08e-05	0.00042	CcSEcCtD
Cladribine—Rash—Cisplatin—urinary bladder cancer	3.07e-05	0.000419	CcSEcCtD
Cladribine—Dermatitis—Cisplatin—urinary bladder cancer	3.07e-05	0.000419	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—urinary bladder cancer	3.07e-05	0.000418	CcSEcCtD
Cladribine—Erythema—Epirubicin—urinary bladder cancer	3.07e-05	0.000418	CcSEcCtD
Cladribine—Diarrhoea—Etoposide—urinary bladder cancer	3.05e-05	0.000417	CcSEcCtD
Cladribine—Nausea—Fluorouracil—urinary bladder cancer	3.05e-05	0.000416	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—urinary bladder cancer	3.05e-05	0.000415	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.04e-05	0.000415	CcSEcCtD
Cladribine—Anaemia—Methotrexate—urinary bladder cancer	3.03e-05	0.000413	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.03e-05	0.000413	CcSEcCtD
Cladribine—Flatulence—Epirubicin—urinary bladder cancer	3.02e-05	0.000412	CcSEcCtD
Cladribine—Back pain—Epirubicin—urinary bladder cancer	2.97e-05	0.000405	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—urinary bladder cancer	2.96e-05	0.000403	CcSEcCtD
Cladribine—Malaise—Methotrexate—urinary bladder cancer	2.96e-05	0.000403	CcSEcCtD
Cladribine—Dizziness—Etoposide—urinary bladder cancer	2.95e-05	0.000403	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—urinary bladder cancer	2.94e-05	0.000402	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	2.94e-05	0.000401	CcSEcCtD
Cladribine—Chills—Doxorubicin—urinary bladder cancer	2.92e-05	0.000399	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—urinary bladder cancer	2.91e-05	0.000397	CcSEcCtD
Cladribine—Nausea—Cisplatin—urinary bladder cancer	2.89e-05	0.000395	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—urinary bladder cancer	2.88e-05	0.000393	CcSEcCtD
Cladribine—Cough—Methotrexate—urinary bladder cancer	2.86e-05	0.00039	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—urinary bladder cancer	2.86e-05	0.000389	CcSEcCtD
Cladribine—Ill-defined disorder—Epirubicin—urinary bladder cancer	2.85e-05	0.000388	CcSEcCtD
Cladribine—Vomiting—Etoposide—urinary bladder cancer	2.84e-05	0.000387	CcSEcCtD
Cladribine—Erythema—Doxorubicin—urinary bladder cancer	2.84e-05	0.000387	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—urinary bladder cancer	2.84e-05	0.000387	CcSEcCtD
Cladribine—Anaemia—Epirubicin—urinary bladder cancer	2.83e-05	0.000387	CcSEcCtD
Cladribine—Rash—Etoposide—urinary bladder cancer	2.82e-05	0.000384	CcSEcCtD
Cladribine—Dermatitis—Etoposide—urinary bladder cancer	2.81e-05	0.000384	CcSEcCtD
Cladribine—Headache—Etoposide—urinary bladder cancer	2.8e-05	0.000381	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—urinary bladder cancer	2.8e-05	0.000381	CcSEcCtD
Cladribine—Myalgia—Methotrexate—urinary bladder cancer	2.79e-05	0.00038	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—urinary bladder cancer	2.79e-05	0.00038	CcSEcCtD
Cladribine—Chest pain—Methotrexate—urinary bladder cancer	2.79e-05	0.00038	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	2.77e-05	0.000378	CcSEcCtD
Cladribine—Malaise—Epirubicin—urinary bladder cancer	2.77e-05	0.000377	CcSEcCtD
Cladribine—Discomfort—Methotrexate—urinary bladder cancer	2.76e-05	0.000376	CcSEcCtD
Cladribine—Back pain—Doxorubicin—urinary bladder cancer	2.74e-05	0.000374	CcSEcCtD
Cladribine—Confusional state—Methotrexate—urinary bladder cancer	2.7e-05	0.000368	CcSEcCtD
Cladribine—Cough—Epirubicin—urinary bladder cancer	2.68e-05	0.000365	CcSEcCtD
Cladribine—Infection—Methotrexate—urinary bladder cancer	2.66e-05	0.000362	CcSEcCtD
Cladribine—Nausea—Etoposide—urinary bladder cancer	2.65e-05	0.000362	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	2.63e-05	0.000359	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—urinary bladder cancer	2.62e-05	0.000358	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—urinary bladder cancer	2.62e-05	0.000358	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.62e-05	0.000357	CcSEcCtD
Cladribine—Myalgia—Epirubicin—urinary bladder cancer	2.61e-05	0.000356	CcSEcCtD
Cladribine—Chest pain—Epirubicin—urinary bladder cancer	2.61e-05	0.000356	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—urinary bladder cancer	2.61e-05	0.000356	CcSEcCtD
Cladribine—Anxiety—Epirubicin—urinary bladder cancer	2.6e-05	0.000355	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—urinary bladder cancer	2.6e-05	0.000354	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.59e-05	0.000354	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—urinary bladder cancer	2.59e-05	0.000353	CcSEcCtD
Cladribine—Discomfort—Epirubicin—urinary bladder cancer	2.58e-05	0.000352	CcSEcCtD
Cladribine—Malaise—Doxorubicin—urinary bladder cancer	2.56e-05	0.000349	CcSEcCtD
Cladribine—Anorexia—Methotrexate—urinary bladder cancer	2.55e-05	0.000348	CcSEcCtD
Cladribine—Confusional state—Epirubicin—urinary bladder cancer	2.52e-05	0.000344	CcSEcCtD
Cladribine—Oedema—Epirubicin—urinary bladder cancer	2.5e-05	0.000341	CcSEcCtD
Cladribine—Hypotension—Methotrexate—urinary bladder cancer	2.5e-05	0.000341	CcSEcCtD
Cladribine—Infection—Epirubicin—urinary bladder cancer	2.49e-05	0.000339	CcSEcCtD
Cladribine—Cough—Doxorubicin—urinary bladder cancer	2.48e-05	0.000338	CcSEcCtD
Cladribine—Nervous system disorder—Epirubicin—urinary bladder cancer	2.45e-05	0.000335	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.45e-05	0.000334	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—urinary bladder cancer	2.44e-05	0.000333	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.44e-05	0.000332	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—urinary bladder cancer	2.43e-05	0.000332	CcSEcCtD
Cladribine—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.42e-05	0.00033	CcSEcCtD
Cladribine—Insomnia—Methotrexate—urinary bladder cancer	2.42e-05	0.00033	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—urinary bladder cancer	2.42e-05	0.000329	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—urinary bladder cancer	2.42e-05	0.000329	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—urinary bladder cancer	2.42e-05	0.000329	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—urinary bladder cancer	2.41e-05	0.000328	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—urinary bladder cancer	2.4e-05	0.000328	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.4e-05	0.000327	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—urinary bladder cancer	2.39e-05	0.000326	CcSEcCtD
Cladribine—Anorexia—Epirubicin—urinary bladder cancer	2.39e-05	0.000325	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—urinary bladder cancer	2.38e-05	0.000325	CcSEcCtD
Cladribine—Somnolence—Methotrexate—urinary bladder cancer	2.38e-05	0.000324	CcSEcCtD
Cladribine—Hypotension—Epirubicin—urinary bladder cancer	2.34e-05	0.000319	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—urinary bladder cancer	2.33e-05	0.000318	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—urinary bladder cancer	2.32e-05	0.000317	CcSEcCtD
Cladribine—Oedema—Doxorubicin—urinary bladder cancer	2.32e-05	0.000316	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.31e-05	0.000315	CcSEcCtD
Cladribine—Fatigue—Methotrexate—urinary bladder cancer	2.31e-05	0.000314	CcSEcCtD
Cladribine—Infection—Doxorubicin—urinary bladder cancer	2.3e-05	0.000314	CcSEcCtD
Cladribine—Pain—Methotrexate—urinary bladder cancer	2.29e-05	0.000312	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.28e-05	0.000311	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.27e-05	0.00031	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.27e-05	0.000309	CcSEcCtD
Cladribine—Insomnia—Epirubicin—urinary bladder cancer	2.26e-05	0.000309	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—urinary bladder cancer	2.26e-05	0.000308	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—urinary bladder cancer	2.25e-05	0.000307	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—urinary bladder cancer	2.25e-05	0.000307	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.24e-05	0.000305	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—urinary bladder cancer	2.23e-05	0.000304	CcSEcCtD
Cladribine—Somnolence—Epirubicin—urinary bladder cancer	2.22e-05	0.000303	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—urinary bladder cancer	2.21e-05	0.000301	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—urinary bladder cancer	2.2e-05	0.000301	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.19e-05	0.000298	CcSEcCtD
Cladribine—Decreased appetite—Epirubicin—urinary bladder cancer	2.18e-05	0.000297	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—urinary bladder cancer	2.16e-05	0.000295	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.16e-05	0.000295	CcSEcCtD
Cladribine—Fatigue—Epirubicin—urinary bladder cancer	2.16e-05	0.000294	CcSEcCtD
Cladribine—Pain—Epirubicin—urinary bladder cancer	2.14e-05	0.000292	CcSEcCtD
Cladribine—Constipation—Epirubicin—urinary bladder cancer	2.14e-05	0.000292	CcSEcCtD
Cladribine—Urticaria—Methotrexate—urinary bladder cancer	2.12e-05	0.00029	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—urinary bladder cancer	2.11e-05	0.000288	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—urinary bladder cancer	2.11e-05	0.000288	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.11e-05	0.000288	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—urinary bladder cancer	2.09e-05	0.000286	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—urinary bladder cancer	2.08e-05	0.000284	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—urinary bladder cancer	2.06e-05	0.000282	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—urinary bladder cancer	2.06e-05	0.000281	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—urinary bladder cancer	2.06e-05	0.000281	CcSEcCtD
Cladribine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.05e-05	0.000279	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—urinary bladder cancer	2.01e-05	0.000275	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2e-05	0.000273	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—urinary bladder cancer	2e-05	0.000272	CcSEcCtD
Cladribine—Urticaria—Epirubicin—urinary bladder cancer	1.99e-05	0.000271	CcSEcCtD
Cladribine—Pain—Doxorubicin—urinary bladder cancer	1.98e-05	0.00027	CcSEcCtD
Cladribine—Constipation—Doxorubicin—urinary bladder cancer	1.98e-05	0.00027	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—urinary bladder cancer	1.98e-05	0.00027	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—urinary bladder cancer	1.98e-05	0.00027	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—urinary bladder cancer	1.97e-05	0.000269	CcSEcCtD
Cladribine—Asthenia—Methotrexate—urinary bladder cancer	1.92e-05	0.000262	CcSEcCtD
Cladribine—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.91e-05	0.00026	CcSEcCtD
Cladribine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.89e-05	0.000258	CcSEcCtD
Cladribine—Pruritus—Methotrexate—urinary bladder cancer	1.89e-05	0.000258	CcSEcCtD
Cladribine—Hypersensitivity—Epirubicin—urinary bladder cancer	1.84e-05	0.000251	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—urinary bladder cancer	1.84e-05	0.000251	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—urinary bladder cancer	1.83e-05	0.00025	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—urinary bladder cancer	1.83e-05	0.00025	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—urinary bladder cancer	1.83e-05	0.00025	CcSEcCtD
Cladribine—Asthenia—Epirubicin—urinary bladder cancer	1.8e-05	0.000245	CcSEcCtD
Cladribine—Pruritus—Epirubicin—urinary bladder cancer	1.77e-05	0.000241	CcSEcCtD
Cladribine—Dizziness—Methotrexate—urinary bladder cancer	1.77e-05	0.000241	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.72e-05	0.000245	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—urinary bladder cancer	1.71e-05	0.000234	CcSEcCtD
Cladribine—DCK—Metabolism—TYMP—urinary bladder cancer	1.71e-05	0.000242	CbGpPWpGaD
Cladribine—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.71e-05	0.000233	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CDKN2A—urinary bladder cancer	1.71e-05	0.000242	CbGpPWpGaD
Cladribine—Vomiting—Methotrexate—urinary bladder cancer	1.7e-05	0.000232	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.69e-05	0.00024	CbGpPWpGaD
Cladribine—Rash—Methotrexate—urinary bladder cancer	1.69e-05	0.00023	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—urinary bladder cancer	1.68e-05	0.00023	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.68e-05	0.000238	CbGpPWpGaD
Cladribine—Headache—Methotrexate—urinary bladder cancer	1.68e-05	0.000228	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TERT—urinary bladder cancer	1.67e-05	0.000238	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—urinary bladder cancer	1.66e-05	0.000227	CcSEcCtD
Cladribine—Dizziness—Epirubicin—urinary bladder cancer	1.65e-05	0.000226	CcSEcCtD
Cladribine—PNP—Metabolism—GPX1—urinary bladder cancer	1.65e-05	0.000235	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NAT2—urinary bladder cancer	1.65e-05	0.000235	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NCOR1—urinary bladder cancer	1.65e-05	0.000234	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—urinary bladder cancer	1.64e-05	0.000223	CcSEcCtD
Cladribine—PNP—Metabolism—ERCC2—urinary bladder cancer	1.62e-05	0.00023	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.62e-05	0.00023	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.61e-05	0.000229	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.61e-05	0.000228	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TERT—urinary bladder cancer	1.61e-05	0.000228	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.61e-05	0.000228	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ENO2—urinary bladder cancer	1.6e-05	0.000228	CbGpPWpGaD
Cladribine—RRM1—Metabolism—HPGDS—urinary bladder cancer	1.6e-05	0.000228	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP9—urinary bladder cancer	1.59e-05	0.000226	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—urinary bladder cancer	1.59e-05	0.000217	CcSEcCtD
Cladribine—Nausea—Methotrexate—urinary bladder cancer	1.59e-05	0.000217	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—urinary bladder cancer	1.58e-05	0.000216	CcSEcCtD
Cladribine—Rash—Epirubicin—urinary bladder cancer	1.58e-05	0.000215	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—urinary bladder cancer	1.58e-05	0.000215	CcSEcCtD
Cladribine—Headache—Epirubicin—urinary bladder cancer	1.57e-05	0.000214	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.56e-05	0.000221	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTT1—urinary bladder cancer	1.56e-05	0.000221	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—ERCC2—urinary bladder cancer	1.55e-05	0.00022	CbGpPWpGaD
Cladribine—DCK—Metabolism—NAT2—urinary bladder cancer	1.54e-05	0.000219	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—urinary bladder cancer	1.53e-05	0.000209	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.53e-05	0.000217	CbGpPWpGaD
Cladribine—PNP—Metabolism—MTHFR—urinary bladder cancer	1.52e-05	0.000216	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EP300—urinary bladder cancer	1.51e-05	0.000215	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—ATM—urinary bladder cancer	1.5e-05	0.000214	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDK4—urinary bladder cancer	1.5e-05	0.000213	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.5e-05	0.000212	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—urinary bladder cancer	1.49e-05	0.000203	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—EP300—urinary bladder cancer	1.48e-05	0.000211	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.48e-05	0.00021	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.48e-05	0.00021	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—urinary bladder cancer	1.47e-05	0.000201	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—SRC—urinary bladder cancer	1.47e-05	0.000209	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	1.47e-05	0.000209	CbGpPWpGaD
Cladribine—Rash—Doxorubicin—urinary bladder cancer	1.46e-05	0.000199	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—urinary bladder cancer	1.46e-05	0.000199	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.46e-05	0.000207	CbGpPWpGaD
Cladribine—Headache—Doxorubicin—urinary bladder cancer	1.45e-05	0.000198	CcSEcCtD
Cladribine—POLE—Cell Cycle—ATM—urinary bladder cancer	1.44e-05	0.000205	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CCND1—urinary bladder cancer	1.44e-05	0.000205	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDK4—urinary bladder cancer	1.44e-05	0.000204	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PPARG—urinary bladder cancer	1.43e-05	0.000202	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.42e-05	0.000201	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.41e-05	0.0002	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.4e-05	0.000199	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.4e-05	0.000199	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—RB1—urinary bladder cancer	1.4e-05	0.000199	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CDKN1A—urinary bladder cancer	1.39e-05	0.000198	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—urinary bladder cancer	1.38e-05	0.000188	CcSEcCtD
Cladribine—RRM2B—Metabolism—CREBBP—urinary bladder cancer	1.37e-05	0.000195	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.37e-05	0.000194	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCNE1—urinary bladder cancer	1.34e-05	0.00019	CbGpPWpGaD
Cladribine—DCK—Metabolism—RRM2—urinary bladder cancer	1.33e-05	0.000189	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—RB1—urinary bladder cancer	1.33e-05	0.000189	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—EP300—urinary bladder cancer	1.33e-05	0.000188	CbGpPWpGaD
Cladribine—RRM2—Metabolism—HPGDS—urinary bladder cancer	1.32e-05	0.000188	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ENO2—urinary bladder cancer	1.32e-05	0.000188	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TYMS—urinary bladder cancer	1.31e-05	0.000187	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.31e-05	0.000186	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—RB1—urinary bladder cancer	1.3e-05	0.000185	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—ESR1—urinary bladder cancer	1.3e-05	0.000184	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.000184	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—urinary bladder cancer	1.29e-05	0.000184	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—urinary bladder cancer	1.29e-05	0.000183	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTT1—urinary bladder cancer	1.28e-05	0.000182	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.28e-05	0.000182	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—RB1—urinary bladder cancer	1.25e-05	0.000178	CbGpPWpGaD
Cladribine—PNP—Metabolism—PPARG—urinary bladder cancer	1.24e-05	0.000176	CbGpPWpGaD
Cladribine—DCK—Metabolism—HPGDS—urinary bladder cancer	1.23e-05	0.000175	CbGpPWpGaD
Cladribine—DCK—Metabolism—ENO2—urinary bladder cancer	1.23e-05	0.000175	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	1.23e-05	0.000175	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TNF—urinary bladder cancer	1.23e-05	0.000174	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.23e-05	0.000174	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—KRAS—urinary bladder cancer	1.22e-05	0.000173	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.2e-05	0.00017	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTT1—urinary bladder cancer	1.2e-05	0.00017	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTZ1—urinary bladder cancer	1.19e-05	0.000169	CbGpPWpGaD
Cladribine—PNP—Metabolism—CREBBP—urinary bladder cancer	1.19e-05	0.000169	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PPARG—urinary bladder cancer	1.18e-05	0.000168	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTZ1—urinary bladder cancer	1.18e-05	0.000167	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MYC—urinary bladder cancer	1.16e-05	0.000164	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.15e-05	0.000163	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN2A—urinary bladder cancer	1.15e-05	0.000163	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TERT—urinary bladder cancer	1.14e-05	0.000163	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.14e-05	0.000162	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—CREBBP—urinary bladder cancer	1.14e-05	0.000161	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.13e-05	0.000161	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTO2—urinary bladder cancer	1.13e-05	0.00016	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NAT1—urinary bladder cancer	1.13e-05	0.00016	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—urinary bladder cancer	1.12e-05	0.000159	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTO2—urinary bladder cancer	1.12e-05	0.000158	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NAT1—urinary bladder cancer	1.12e-05	0.000158	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN2A—urinary bladder cancer	1.1e-05	0.000156	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTZ1—urinary bladder cancer	1.1e-05	0.000156	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.08e-05	0.000154	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000153	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NQO1—urinary bladder cancer	1.06e-05	0.000151	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1.05e-05	0.000149	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NAT1—urinary bladder cancer	1.04e-05	0.000148	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTO2—urinary bladder cancer	1.04e-05	0.000148	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	1.04e-05	0.000147	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—urinary bladder cancer	1.03e-05	0.000147	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	1.03e-05	0.000146	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—ATM—urinary bladder cancer	1.03e-05	0.000146	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDK4—urinary bladder cancer	1.02e-05	0.000145	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—UGT2B7—urinary bladder cancer	1.02e-05	0.000145	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.01e-05	0.000143	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	1e-05	0.000143	CbGpPWpGaD
Cladribine—RRM1—Metabolism—TYMS—urinary bladder cancer	1e-05	0.000142	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—RB1—urinary bladder cancer	9.96e-06	0.000141	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—EP300—urinary bladder cancer	9.96e-06	0.000141	CbGpPWpGaD
Cladribine—DCK—Metabolism—NQO1—urinary bladder cancer	9.95e-06	0.000141	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTM1—urinary bladder cancer	9.91e-06	0.000141	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NCOR1—urinary bladder cancer	9.91e-06	0.000141	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTEN—urinary bladder cancer	9.78e-06	0.000139	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—urinary bladder cancer	9.73e-06	0.000138	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—urinary bladder cancer	9.67e-06	0.000137	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.58e-06	0.000136	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—EP300—urinary bladder cancer	9.56e-06	0.000136	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—UGT2B7—urinary bladder cancer	9.51e-06	0.000135	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—urinary bladder cancer	9.49e-06	0.000135	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GPX1—urinary bladder cancer	9.49e-06	0.000135	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.49e-06	0.000135	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN1A—urinary bladder cancer	9.36e-06	0.000133	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—EP300—urinary bladder cancer	9.33e-06	0.000132	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ERCC2—urinary bladder cancer	9.32e-06	0.000132	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—urinary bladder cancer	9.29e-06	0.000132	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	9.29e-06	0.000132	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP4B1—urinary bladder cancer	9.19e-06	0.00013	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN1A—urinary bladder cancer	8.98e-06	0.000128	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—RB1—urinary bladder cancer	8.91e-06	0.000127	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—EP300—urinary bladder cancer	8.91e-06	0.000126	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTP1—urinary bladder cancer	8.88e-06	0.000126	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.84e-06	0.000126	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	8.77e-06	0.000125	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	8.76e-06	0.000124	CbGpPWpGaD
Cladribine—RRM1—Metabolism—MTHFR—urinary bladder cancer	8.76e-06	0.000124	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC19A1—urinary bladder cancer	8.68e-06	0.000123	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—urinary bladder cancer	8.68e-06	0.000123	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP4B1—urinary bladder cancer	8.57e-06	0.000122	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—EP300—urinary bladder cancer	8.55e-06	0.000121	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PRSS3—urinary bladder cancer	8.55e-06	0.000121	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—urinary bladder cancer	8.48e-06	0.00012	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PRSS3—urinary bladder cancer	8.46e-06	0.00012	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—urinary bladder cancer	8.33e-06	0.000118	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTP1—urinary bladder cancer	8.3e-06	0.000118	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TYMS—urinary bladder cancer	8.25e-06	0.000117	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NCOR1—urinary bladder cancer	8.16e-06	0.000116	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTM1—urinary bladder cancer	8.16e-06	0.000116	CbGpPWpGaD
Cladribine—PNP—Metabolism—EP300—urinary bladder cancer	8.09e-06	0.000115	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC19A1—urinary bladder cancer	8.09e-06	0.000115	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PRSS3—urinary bladder cancer	7.88e-06	0.000112	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—urinary bladder cancer	7.83e-06	0.000111	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GPX1—urinary bladder cancer	7.81e-06	0.000111	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—urinary bladder cancer	7.76e-06	0.00011	CbGpPWpGaD
Cladribine—DCK—Metabolism—TYMS—urinary bladder cancer	7.71e-06	0.00011	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ERCC2—urinary bladder cancer	7.67e-06	0.000109	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTM1—urinary bladder cancer	7.63e-06	0.000108	CbGpPWpGaD
Cladribine—DCK—Metabolism—NCOR1—urinary bladder cancer	7.63e-06	0.000108	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—urinary bladder cancer	7.45e-06	0.000106	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	7.4e-06	0.000105	CbGpPWpGaD
Cladribine—DCK—Metabolism—GPX1—urinary bladder cancer	7.3e-06	0.000104	CbGpPWpGaD
Cladribine—RRM2—Metabolism—MTHFR—urinary bladder cancer	7.21e-06	0.000102	CbGpPWpGaD
Cladribine—DCK—Metabolism—ERCC2—urinary bladder cancer	7.17e-06	0.000102	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	7.16e-06	0.000102	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PPARG—urinary bladder cancer	7.1e-06	0.000101	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMP—urinary bladder cancer	6.83e-06	9.7e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CREBBP—urinary bladder cancer	6.82e-06	9.69e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—EP300—urinary bladder cancer	6.81e-06	9.67e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMP—urinary bladder cancer	6.76e-06	9.6e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—MTHFR—urinary bladder cancer	6.74e-06	9.57e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—urinary bladder cancer	6.74e-06	9.57e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—urinary bladder cancer	6.62e-06	9.4e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1A—urinary bladder cancer	6.4e-06	9.09e-05	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—urinary bladder cancer	6.37e-06	9.05e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMP—urinary bladder cancer	6.3e-06	8.95e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NAT2—urinary bladder cancer	6.18e-06	8.77e-05	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—urinary bladder cancer	6.12e-06	8.69e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NAT2—urinary bladder cancer	6.11e-06	8.68e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—EP300—urinary bladder cancer	6.09e-06	8.65e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—urinary bladder cancer	5.94e-06	8.43e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPARG—urinary bladder cancer	5.85e-06	8.3e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NAT2—urinary bladder cancer	5.7e-06	8.09e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CREBBP—urinary bladder cancer	5.62e-06	7.98e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—urinary bladder cancer	5.59e-06	7.93e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPARG—urinary bladder cancer	5.46e-06	7.76e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—RRM2—urinary bladder cancer	5.33e-06	7.57e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—urinary bladder cancer	5.31e-06	7.54e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—RRM2—urinary bladder cancer	5.28e-06	7.49e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—CREBBP—urinary bladder cancer	5.25e-06	7.45e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.02e-06	7.13e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—urinary bladder cancer	4.94e-06	7.01e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HPGDS—urinary bladder cancer	4.94e-06	7.01e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—RRM2—urinary bladder cancer	4.92e-06	6.99e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	4.89e-06	6.94e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—urinary bladder cancer	4.89e-06	6.94e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—urinary bladder cancer	4.87e-06	6.92e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTT1—urinary bladder cancer	4.79e-06	6.8e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	4.74e-06	6.73e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.68e-06	6.65e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—EP300—urinary bladder cancer	4.65e-06	6.6e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—urinary bladder cancer	4.6e-06	6.53e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—urinary bladder cancer	4.56e-06	6.47e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	4.56e-06	6.47e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.49e-06	6.37e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.44e-06	6.3e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	4.42e-06	6.27e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—urinary bladder cancer	4.36e-06	6.19e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—urinary bladder cancer	4.3e-06	6.1e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.14e-06	5.87e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—urinary bladder cancer	4.01e-06	5.7e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NQO1—urinary bladder cancer	3.98e-06	5.65e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NQO1—urinary bladder cancer	3.94e-06	5.59e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	3.85e-06	5.46e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—EP300—urinary bladder cancer	3.83e-06	5.43e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—urinary bladder cancer	3.75e-06	5.32e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NQO1—urinary bladder cancer	3.67e-06	5.21e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	3.59e-06	5.09e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—EP300—urinary bladder cancer	3.58e-06	5.08e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTP1—urinary bladder cancer	3.32e-06	4.71e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	3.29e-06	4.67e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—urinary bladder cancer	3.09e-06	4.38e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	3.06e-06	4.35e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—urinary bladder cancer	3.06e-06	4.34e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTM1—urinary bladder cancer	3.05e-06	4.33e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NCOR1—urinary bladder cancer	3.05e-06	4.33e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	3.02e-06	4.29e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	3.02e-06	4.29e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.92e-06	4.15e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPX1—urinary bladder cancer	2.89e-06	4.11e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.87e-06	4.07e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—urinary bladder cancer	2.85e-06	4.04e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	2.84e-06	4.03e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	2.81e-06	4e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	2.81e-06	4e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.7e-06	3.83e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPX1—urinary bladder cancer	2.7e-06	3.83e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	2.67e-06	3.79e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	2.65e-06	3.76e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	2.49e-06	3.53e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.19e-06	3.11e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPARG—urinary bladder cancer	2.16e-06	3.07e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.1e-06	2.98e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	2.08e-06	2.95e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	2.02e-06	2.86e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	1.94e-06	2.75e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.72e-06	2.44e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	1.7e-06	2.42e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	1.59e-06	2.25e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.5e-06	2.13e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	1.48e-06	2.11e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—EP300—urinary bladder cancer	1.43e-06	2.03e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—EP300—urinary bladder cancer	1.42e-06	2.01e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	1.38e-06	1.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—EP300—urinary bladder cancer	1.32e-06	1.87e-05	CbGpPWpGaD
